Remedent, Inc. Stock

REMI

US75954T1043

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 10:41:52 2026-09-09 EDT			5-day change	1st Jan Change
0.000800 ^USD	+14.29%		0.00%	+33.33%

23-11-21	Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
22-09-19	Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	CI

Remedent, Inc. specializes in the research, development and manufacturing of oral care and cosmetic dentistry products. The Company designs, develops, manufactures and distributes its cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, Middle East and the United States. The Company's operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., and Biotech Dental Benelux N.V. The Company offers over-the-counter (OTC) tooth whitening products. It has three primary products: River 8, a prefabricated veneer; its custom-made GlamSmile Veneers and the SmileMe mirror. The Company has developed a range of prefabricated, ready-to-use veneers that the Company has branded as River8. The Company's product in the professional oral care and cosmetic dentistry is the GlamSmile veneer. The SmileMe Mirror enables the dentist to offer patients a complete Smile Consultation.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Stock Market
Stocks
REMI Stock

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	1.31M 1.51M 1.24M 1.13M 2.11M 145M 2.12M 14.86M 5.73M 73.48M 5.66M 5.53M 236M	P/E 2022 *	-	P/E 2023	-
Enterprise Value	1.29M 1.47M 1.21M 1.1M 2.07M 141M 2.07M 14.54M 5.61M 71.93M 5.54M 5.42M 231M	EV / Sales 2022	7.45x	EV / Sales 2023	65.9x
Free-Float	61.46%	Yield 2022 *	-	Yield 2023	-

23-11-21	Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
22-09-19	Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	CI
21-06-01	Remedent Announces Agreement with Aurum Ceramic Dental Laboratories Co., Concerning an Exclusive Master License Agreement in Reference to Its Glamsmile Veneers and Technology	CI
21-02-16	Remedent, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2020	CI
20-11-16	Remedent, Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2020	CI
20-08-14	Remedent, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	CI
20-06-30	Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	CI
20-02-14	Remedent, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	CI
19-11-14	Remedent, Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	CI
19-08-14	Remedent, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	CI
19-06-28	Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	CI
19-02-14	Remedent, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	CI
17-08-14	Remedent, Inc Reports Financial Results for the First Quarter Ended June 30, 2017	CI

22-06-30	Remedent : Attorney Letter - Lockett + Horwitz - Remedent, Inc. 2022-06-30 - re Annual Report	PU
22-06-29	Remedent : Annual Report for Year Ended March 31, 2022	PU
21-06-30	REMEDENT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-06-30	Remedent, Inc. Files Form 15 to Suspend SEC Exchange Act Registration and Applies to Qualify for OTC Markets Alternative Reporting Standard for Pink Sheet Companies	GL
21-06-01	Remedent announces its agreement with Aurum Ceramic Dental Laboratories Co., concerning an Exclusive Master License Agreement in reference to its GlamSmile Veneers and Technology	GL

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.15
5 years	0		0.24
10 years	0		0.43

Manager	Title	Age	Since
Guy de Vreese CEO	Chief Executive Officer	71	2008-12-09
Philippe van Acker DFI	Director of Finance/CFO	61	2012-07-16

Remedent, Inc. Stock

Stocks

REMI

US75954T1043

Medical Equipment, Supplies & Distribution

Valuation: Remedent, Inc.

Chart: Remedent, Inc.

Latest news: Remedent, Inc.

Press Releases: Remedent, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Remedent, Inc.

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

1 day	+14.29%
Current month	+14.29%
1 month	+14.29%
3 months	+14.29%
6 months	+14.29%
Current year	+33.33%

Director	Title	Age	Since
Guy de Vreese CHM	Chairman	71	2002-03-31
Philippe van Acker BRD	Director/Board Member	61	2011-01-30
Fred Kolsteeg BRD	Director/Board Member	83	2002-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REMEDENT, INC.	+14.29%	0.00%	-91.09%	-99.53%	15.42K
ABBOTT LABORATORIES	+0.37%	+0.65%	-24.57%	+2.32%	178B
MEDTRONIC PLC	-0.69%	+1.29%	-3.10%	+13.07%	118B
CENCORA, INC.	-0.20%	-3.98%	+6.47%	+68.94%	58.92B
BECTON, DICKINSON AND COMPANY	-0.24%	+1.74%	-3.26%	-32.27%	49.29B
HOYA CORPORATION	-0.22%	-0.37%	+10.27%	+42.75%	48.17B
DEXCOM, INC.	+1.61%	+7.61%	+32.47%	-3.54%	33.72B
MEDLINE INC.	-1.49%	-2.74%	-	-	27.76B
WEST PHARMACEUTICAL SERVICES, INC.	-1.17%	+4.64%	+42.17%	-5.73%	25.5B
SARTORIUS STEDIM BIOTECH	+1.02%	+5.99%	+6.51%	-17.36%	22.1B
Average	+1.33%	+1.67%	-2.68%	-3.48%	56.09B
Weighted average by Cap.	-0.08%	+1.03%	-3.19%	+10.95%

	2022	2023
Net sales	402K 461K 379K 345K 646K 44.23M 648K 4.55M 1.75M 22.48M 1.73M 1.69M 72.35M	46.11K 52.88K 43.54K 39.54K 74.08K 5.07M 74.39K 522K 201K 2.58M 199K 194K 8.3M
Net income	132K 151K 125K 113K 212K 14.51M 213K 1.49M 576K 7.38M 568K 555K 23.74M	-304K -349K -287K -261K -489K -33.47M -491K -3.44M -1.33M -17.02M -1.31M -1.28M -54.75M
Net Debt	-2.52K -2.89K -2.38K -2.16K -4.05K -277K -4.06K -28.49K -10.99K -141K -10.85K -10.61K -453K	-27.69K -31.75K -26.15K -23.74K -44.48K -3.05M -44.67K -313K -121K -1.55M -119K -117K -4.98M